Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.79+0.45%BTC$85,618.00-0.20%ETH$2,695.89-0.68%GOLD$4,191.90+0.84%OIL$89.82+0.44%
Smart Investors Daily
SID Premium
NC

NASDAQ · NCNA

NuCana plc

Healthcare · Biotechnology

$1.06

Up+$0.03 (+2.83%)

Updated Oct 6, 2026, 8:06 PM

SID Score

2.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
24.41M
P/E ratio
-0.1
Dividend yield
0.00%
52-week range
$0.95 – $2.39
Volume
71.75K
Avg. volume
362.72K

Price performance · NCNA

NCNA price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

NCNA closed at $1.06 after 20 trading sessions, down 24.29% for the selected period.

Last close
$1.06
Period change
-24.29%
Period low
$1.06
Period high
$1.40
Daily close
View OHLC price history
NCNA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$1.12$1.12$1.0301$1.0671.75K
Oct 2, 2026$1.18$1.22$0.9484$1.09326.01K
Oct 1, 2026$1.29$1.3131$1.01$1.17804.73K
Sep 30, 2026$1.29$1.44$1.26$1.353.3M
Sep 29, 2026$1.29$1.29$1.21$1.2124.81K
Sep 28, 2026$1.32$1.3695$1.26$1.2923.67K
Sep 25, 2026$1.30$1.35$1.21$1.2838.65K
Sep 24, 2026$1.31$1.34$1.2716$1.329.28K
Sep 23, 2026$1.33$1.35$1.30$1.3127.84K
Sep 22, 2026$1.3477$1.38$1.30$1.3320.55K
Sep 21, 2026$1.35$1.39$1.32$1.3226.38K
Sep 18, 2026$1.33$1.385$1.32$1.3410.97K
Sep 17, 2026$1.33$1.37$1.30$1.3347.24K
Sep 16, 2026$1.31$1.3315$1.30$1.3019.2K
Sep 15, 2026$1.32$1.35$1.30$1.3065.81K
Sep 14, 2026$1.34$1.37$1.3105$1.3213.69K
Sep 11, 2026$1.34$1.3624$1.32$1.3225.12K
Sep 10, 2026$1.36$1.375$1.34$1.3427.03K
Sep 9, 2026$1.40$1.44$1.37$1.3717.2K
Sep 8, 2026$1.42$1.43$1.40$1.4021.66K

Latest NCNA news

The latest Smart Investors Daily articles mentioning NCNA.

Stock researchCompany · Overview

NCNA research

Overview

Company profile and research snapshot.

Company profile

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
NCNA recent ratings
DateFirmRatingTarget
Sep 3, 2024OppenheimerOutperform—
Aug 30, 2024William BlairMarket Perform—
Aug 19, 2024OppenheimerOutperform—
Jul 23, 2024OppenheimerOutperform—
Jul 22, 2024OppenheimerOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 30, 2026

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe

NUC-7738 is protected by over 85 issued patents worldwideEDINBURGH, United Kingdom, Sept. 30, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced that the European Patent Office (“EPO”) has granted an important patent covering the composition of matter for NUC-7738. This patent (EP 3683225) is a key component of the patent protection for NUC-7738, which currently consists of over 85 issued patents worldwide. The composition-of-matter patent covers the chemica

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By